ImpriMed Korea

Find the best drugs for treating cancer
BEFORE treatment begins

We use functional assays and artificial intelligence to provide personalized predictions on survival and response.

Technology

We analyze traits of each patient’s cancer cells to predict his or her survival and response specific to the choice of chemotherapeutic regimen. The predictive information can help to identify an optimal treatment for each patient.  

Human Oncology Pipeline

Precision medicine services for individual blood cancer patients and CRO services for pharmaceutical companies screening a successful drug candidate

STAGE
R&D
COMMERCIAL
R&D
COMMERCIAL
Service
Indication/Type
Tech Development
Clinical Study
Innovative Tech Approval
Approval
Sales
IMK-MM-1
Multiple myeloma (MM) treatment selection
IMK-AML-1
Acute myeloid leukemia treatment selection
IMK-NHL-1
Non-Hodgkin lymphoma treatment selection
IMK-RA-1
Rheumatoid arthritis treatment selection
IMK-MM-1
Multiple myeloma (MM) treatment selection
IMK-AML-1
Acute myeloid leukemia treatment selection
IMK-NHL-1
Non-Hodgkin lymphoma treatment selection
IMK-RA-1
Rheumatoid arthritis treatment selection
IMK-MM-1
Multiple myeloma (MM) treatment selection
IMK-AML-1
Acute myeloid leukemia treatment selection
IMK-NHL-1
Non-Hodgkin lymphoma treatment selection
IMK-RA-1
Rheumatoid arthritis treatment selection
Current
Plan by Q3 of 2024
Personalized Prediction Profile provides detailed information about your dog's cancer cells and predictions on response to anticancer drugs
New service

Personalized Prediction Profile for Canine Lymphoma and Leukemia

We measure how your dog's live cancer cells respond to different anticancer drugs. Then we use artificial intelligence (AI) to combine these measurements with other biological information to predict which drugs are most likely to be effective for your dog's lymphoma or leukemia.

Our mission is to empower clinicians and help patients with the best predictive information for personalized cancer care.

Our Milestones

2018
  • Opened ImpriMed Korea office
  • Received seed funding
2019
  • Received the Korean Venture Accreditation
  • Admitted to the Seoul Startup Hub
2020
  • Acquired IRB approval for the R&D on precision medicine technology for human blood cancer
  • Received a research grant ($370,000) from the Seoul Business Administration
2021
  • Won 4th place in the AI model development national competition held by the Ministry of Science and ICT in Korea
  • Received the research grant ($280,000) from the National Industry Promotion Agency
  • Nominated as one of the Top 100 Korean AI start-ups
  • Filed 3rd patent titled Predicting Clinical Outcome or Prognosis of Cancer Treatment based on Machine Learning
  • Received a research grant ($80,000) from the National Research Foundation of Korea
2022
  • Signed MOU with The Catholic University Seoul St. Mary's Hospital
  • Selected to the Mayo Clinic Platform Accelerate Program 2022
  • Presented our AI precision medicine technology for newly diagnosed multiple myeloma patients at the International Myeloma Society 2022
2023
  • Published an article about NDMM-1 in Nature Portfolio(npj) Precision Oncology
  • Relocated ImpriMedKorea’s office and research facilities to DMC Hi-Tech Business Center
  • Launched the IMV services for canine lymphoma and leukemia
  • Was nominated as one of the Top 100 Korean AI start-ups for 2023
  • IMV kit designated as an innovative product by the South Korean Public Procurement Service (PPS)
  • NDMM-1, designated as an innovative medical device by the South Korean Ministry of Food and Drug Safety (MFDS)
2024
  • Obtained In Vitro Diagnostic Medical Devices manufacturing permission from the South Korean Ministry of Food and Drug Safety (MFDS)
  • Presented our scientific poster at European Alliance of Associations for Rheumatology
  • Presented our abstract and scientific poster at World Veterinary Cancer Congress Tokyo 2024
Today
ImpriMed is bringing together our expertise in humans and canines to accelerate the development of AI-driven personalized medicine solutions for all cancer patients.

Our Team

A profile image of Sungwon Lim, CEO & Co-Founder at ImpriMed, Inc.
Co-Founder & CEO
Board Director

Sungwon Lim

A profile image of Jamin Koo, Director & Co-Founder at ImpriMed, Inc.
Co-Founder & CTO
Board Director

Jamin Koo

Senior Data Scientist

Gyucheol Choi

Strategy Manager

Hojung Park

Senior Research Associate

Seunghyeok Ham

Research Associate

Seongjoon Lee

Software Engineer

Heeju Choi

Executive Assistant

Jungwoon Bae

Research Associate

Sesun Park

Operations Manager

Sungjin Park

Quality Assurance(QA) Manager

Haeun Cho

Software Engineer

Taeyoung Choi

advisors & board directors

Medical Advisor

Jong Cheol Lee

MD, PhD

GangNeung Asan Hospital

Dept of Otorhinolaryngology
Medical Advisor

Sung-soo Park

MD, PhD

The Catholic Univ. of Korea, Seoul St. Mary's Hospital

Dept of Hematology
Medical Advisor

Sung-han Kim

MD, PhD

Asan Medical Center

Dept of Infectious Diseases, Dept of Hematologic Cancer & BMT Center

Offices

ImpriMed Korea has received support from:

GangNeung Asan HospitalThe Catholic University of Korea Seoul St. Mary's HospitalImpriMed completed Mayo Clinic Platform_Accelerate program

Join our growing team!

Contact Us

Please fill out the form to get in touch with us.
We’ll get back to you within 1-2 business days.

Email us

General inquiries – imprimedkorea@imprimedicine.com